StockData
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Inmune Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.54−0.03 (-1.91%)

Close on Oct 19, 2026

Market cap
$41.15M
P/E (TTM)
–
Dividend yield
–

Earnings

Quarterly results announced on Form 8-K, Item 2.02

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2025
Ended Sep 30, 2025
Oct 30, 2025During market hours–––
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours–$-1.05–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025During market hours$50.00K$-0.43–
Q4 FY2024
Ended Dec 31, 2024
Mar 27, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Nov 1, 2024During market hours–$-0.60–
Q2 FY2024
Ended Jun 30, 2024
Aug 2, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Mar 29, 2024During market hours–––
Q3 FY2023
Ended Sep 30, 2023
Nov 1, 2023During market hours–––
Q2 FY2023
Ended Jun 30, 2023
Aug 8, 2023During market hours–––
Q1 FY2023
Ended Mar 31, 2023
May 4, 2023During market hours–––
Q4 FY2022
Ended Dec 31, 2022
Mar 3, 2023During market hours–––

Press releases

Announcements Inmune Bio filed with the SEC